RS52216B - Jedinjenja i metode za modulaciju fxr-a - Google Patents

Jedinjenja i metode za modulaciju fxr-a

Info

Publication number
RS52216B
RS52216B RS20120099A RSP20120099A RS52216B RS 52216 B RS52216 B RS 52216B RS 20120099 A RS20120099 A RS 20120099A RS P20120099 A RSP20120099 A RS P20120099A RS 52216 B RS52216 B RS 52216B
Authority
RS
Serbia
Prior art keywords
phenyl
cyclopropyl
dichloro
isoxazol
methyl
Prior art date
Application number
RS20120099A
Other languages
English (en)
Serbian (sr)
Inventor
Michael James Genin
Melendo Ana Belen Bueno
Peter Rudolph Manninen
Alan M. Warshawsky
Francisco Javier Agejas-Chicharro
Original Assignee
Eli Lilly & Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly & Company filed Critical Eli Lilly & Company
Publication of RS52216B publication Critical patent/RS52216B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
RS20120099A 2007-07-16 2008-07-11 Jedinjenja i metode za modulaciju fxr-a RS52216B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94997407P 2007-07-16 2007-07-16
PCT/US2008/069719 WO2009012125A1 (en) 2007-07-16 2008-07-11 Compounds and methods for modulating fxr

Publications (1)

Publication Number Publication Date
RS52216B true RS52216B (sr) 2012-10-31

Family

ID=39855171

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20120099A RS52216B (sr) 2007-07-16 2008-07-11 Jedinjenja i metode za modulaciju fxr-a

Country Status (31)

Country Link
US (1) US8153624B2 (cg-RX-API-DMAC7.html)
EP (1) EP2178851B1 (cg-RX-API-DMAC7.html)
JP (1) JP5373788B2 (cg-RX-API-DMAC7.html)
KR (1) KR101157334B1 (cg-RX-API-DMAC7.html)
CN (1) CN101743232B (cg-RX-API-DMAC7.html)
AR (1) AR067540A1 (cg-RX-API-DMAC7.html)
AT (1) ATE539065T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008276236B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0814571A2 (cg-RX-API-DMAC7.html)
CA (1) CA2693406C (cg-RX-API-DMAC7.html)
CL (1) CL2008002051A1 (cg-RX-API-DMAC7.html)
CO (1) CO6270212A2 (cg-RX-API-DMAC7.html)
CY (1) CY1112298T1 (cg-RX-API-DMAC7.html)
DK (1) DK2178851T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2010000018A (cg-RX-API-DMAC7.html)
EA (1) EA016475B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP109879A (cg-RX-API-DMAC7.html)
ES (1) ES2376176T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120048T1 (cg-RX-API-DMAC7.html)
IL (1) IL202234A0 (cg-RX-API-DMAC7.html)
MA (1) MA31683B1 (cg-RX-API-DMAC7.html)
MX (1) MX2010000502A (cg-RX-API-DMAC7.html)
PE (1) PE20090809A1 (cg-RX-API-DMAC7.html)
PL (1) PL2178851T3 (cg-RX-API-DMAC7.html)
PT (1) PT2178851E (cg-RX-API-DMAC7.html)
RS (1) RS52216B (cg-RX-API-DMAC7.html)
SI (1) SI2178851T1 (cg-RX-API-DMAC7.html)
SV (1) SV2010003458A (cg-RX-API-DMAC7.html)
TN (1) TN2010000028A1 (cg-RX-API-DMAC7.html)
TW (1) TW200906823A (cg-RX-API-DMAC7.html)
WO (1) WO2009012125A1 (cg-RX-API-DMAC7.html)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289883A1 (en) * 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN103370315A (zh) * 2010-12-20 2013-10-23 Irm责任有限公司 用于调控法尼醇x受体的组合物和方法
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2655369A1 (en) * 2010-12-20 2013-10-30 Irm Llc Compositions and methods for modulating farnesoid x receptors
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
HRP20201953T1 (hr) 2013-09-11 2021-04-30 Institut National De La Santé Et De La Recherche Médicale (Inserm) Postupci i farmaceutski pripravci za liječenje virusne infekcije hepatitisom b
DK3065738T3 (en) 2013-11-05 2018-06-06 Novartis Ag Compositions and Methods for Modulating Farnesoid X Receptors
CN104045635A (zh) * 2014-06-23 2014-09-17 华东理工大学 3,4,5-三取代异恶唑类化合物及其用途
EP3006939A1 (en) 2014-10-06 2016-04-13 Gilead Sciences, Inc. Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3034499A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
TN2017000344A1 (en) 2015-02-06 2019-01-16 Intercept Pharmaceuticals Inc Pharmaceutical compositions for combination therapy
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
PL3277286T3 (pl) 2015-03-31 2021-11-08 Enanta Pharmaceuticals, Inc. Pochodne kwasu żółciowego jako agonisty fxr/tgr5 i sposoby ich stosowania
MX2017012893A (es) 2015-04-07 2018-01-15 Intercept Pharmaceuticals Inc Composiciones farmaceuticas para terapias combinadas.
CN106946867B (zh) * 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
CN107021958A (zh) * 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
US11419878B2 (en) 2016-03-28 2022-08-23 Intercept Pharmaceuticals, Inc. Medicine obtained by combining FXR agonist and ARB
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
WO2017201150A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
US10138228B2 (en) 2016-05-18 2018-11-27 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use therof
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
KR102269305B1 (ko) 2016-06-13 2021-06-25 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
WO2018039384A1 (en) 2016-08-23 2018-03-01 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators
CN116854681A (zh) 2016-08-23 2023-10-10 阿德利克斯股份有限公司 用于治疗代谢病状和病症的激素受体调节剂
RU2019110779A (ru) * 2016-09-14 2020-10-15 Новартис Аг Новые схемы введения агонистов fxr
AU2017338853A1 (en) * 2016-10-04 2019-04-18 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
CN108017636A (zh) * 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
CN108218852A (zh) * 2016-12-15 2018-06-29 宁波百纳西药业有限公司 一种螺环化合物、其制备方法、组合物及用途
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
EP3600293A1 (en) 2017-03-30 2020-02-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
HRP20220026T1 (hr) 2017-04-12 2022-04-01 Il Dong Pharmaceutical Co., Ltd. Derivati izoksazola kao agonisti nuklearnog receptora i njihove uporabe
CN109265471B (zh) * 2017-06-30 2021-06-04 轩竹生物科技有限公司 Fxr受体激动剂
CN109320509B (zh) * 2017-07-31 2022-02-08 轩竹生物科技股份有限公司 Fxr受体激动剂
EP3681881B1 (en) 2017-09-14 2022-11-02 Ardelyx, Inc. Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders
WO2019089670A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Alkene compounds as farnesoid x receptor modulators
ES2964964T3 (es) 2017-11-01 2024-04-10 Bristol Myers Squibb Co Compuestos bicíclicos puenteados como moduladores del receptor X farnesoide
SG11202003830SA (en) 2017-11-01 2020-05-28 Bristol Myers Squibb Co Alkene spirocyclic compounds as farnesoid x receptor modulators
MX2020004400A (es) 2017-11-01 2020-08-06 Bristol Myers Squibb Co Compuestos espirociclicos como moduladores del receptor farnesoide x.
ES2944601T3 (es) 2017-11-01 2023-06-22 Bristol Myers Squibb Co Compuestos multicíclicos como moduladores del receptor farnesoide X
WO2019118571A1 (en) 2017-12-12 2019-06-20 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
CN111263759B (zh) * 2017-12-22 2023-03-28 四川科伦博泰生物医药股份有限公司 异噁唑衍生物及其制备方法和用途
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
CN110452235B (zh) * 2018-05-08 2023-02-17 中国科学院上海药物研究所 一类含氟异噁唑类化合物及其制备方法、药物组合物和用途
MX2021002305A (es) * 2018-08-30 2021-05-31 Terns Pharmaceuticals Inc Tratamiento de trastornos del higado.
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
DK3911647T3 (da) 2019-01-15 2024-02-26 Gilead Sciences Inc Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
US12227496B2 (en) 2019-02-15 2025-02-18 Bristol-Myers Squibb Company Substituted bicyclic compounds as farnesoid X receptor modulators
MX2021009564A (es) 2019-02-15 2021-09-08 Bristol Myers Squibb Co Compuestos de amida sustituida utiles como moduladores del receptor de farnesoide x.
EA202192275A1 (ru) 2019-02-15 2021-11-03 Бристол-Маерс Сквибб Компани Замещенные амидные соединения, полезные в качестве модуляторов фарнезоидного x-рецептора
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
CN118388474A (zh) 2019-02-19 2024-07-26 吉利德科学公司 Fxr激动剂的固体形式
IL287159B1 (en) 2019-04-19 2025-10-01 Shanghai Inst Materia Medica Cas Small molecules agonists for FXR (farnesoid X receptor) and method for their preparation and use
WO2020231917A1 (en) * 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
AU2020284135A1 (en) 2019-05-30 2022-01-06 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a FXR agonist and a fibrate for use in the treatment of cholestatic liver disease
US20220241376A1 (en) 2019-07-18 2022-08-04 Enyo Pharma Method for decreasing adverse-effects of interferon
WO2021050945A1 (en) 2019-09-12 2021-03-18 Terns, Inc. Thyroid hormone receptor beta agonist compounds
CA3160445A1 (en) * 2019-11-08 2021-05-14 Terns Pharmaceuticals, Inc. Treating liver disorders
WO2021108974A1 (en) 2019-12-03 2021-06-10 Gannex Pharma Co., Ltd Compounds for modulating activity of fxr and uses thereof
CA3159163A1 (en) 2020-01-15 2021-07-22 Raphael Darteil Use of fxr agonists for treating an infection by hepatitis d virus
EP4149452A4 (en) * 2020-05-13 2024-05-01 Terns Pharmaceuticals, Inc. COMBINATION TREATMENT OF LIVER DISEASES
KR20230058112A (ko) 2020-08-25 2023-05-02 일라이 릴리 앤드 캄파니 Ssao 억제제의 다형체
IL301238A (en) * 2020-09-11 2023-05-01 Terns Pharmaceuticals Inc Solid dispersion formulations of an fxr agonist
WO2022082197A1 (en) * 2020-10-15 2022-04-21 Eli Lilly And Company Polymorphs of an fxr agonist
US20240100125A1 (en) 2021-01-14 2024-03-28 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
CA3213217A1 (en) 2021-04-28 2022-11-03 Raphael Darteil Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
CN119013027A (zh) 2021-11-11 2024-11-22 拓臻制药公司 用于治疗肝脏病症的SSAO抑制剂和THR-β激动剂的组合
WO2023220404A1 (en) * 2022-05-13 2023-11-16 Terns Pharmaceuticals, Inc. Treatment of non-alcoholic steatohepatitis
CN115850152B (zh) * 2022-12-20 2025-10-31 河北鼎泰制药有限公司 一种杂质A-7-imp3的制备方法及其用途
TW202506131A (zh) 2023-04-07 2025-02-16 美商拓臻製藥公司 ＧＬＰ－１Ｒ及ＴＨＲβ激動劑之組合以及其使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138258A (ja) * 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
EP1140079B1 (en) 1998-12-23 2009-06-03 Glaxo Group Limited Assays for ligands for nuclear receptors
US6967212B2 (en) * 2001-05-30 2005-11-22 Bristol-Myers Squibb Company Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US7105556B2 (en) * 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
CN1665500A (zh) 2002-07-09 2005-09-07 百时美施贵宝公司 用作抗糖尿病和抗肥胖症试剂的取代杂环衍生物及方法
JP2006515838A (ja) * 2002-11-22 2006-06-08 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
CA2640476A1 (en) * 2006-02-03 2007-08-16 Eli Lilly And Company Compounds and methods for modulating fx-receptors
CA2651378C (en) 2006-05-24 2012-08-28 Eli Lilly And Company Fxr agonists
TW200812982A (en) 2006-05-24 2008-03-16 Lilly Co Eli Compounds and methods for modulating FXR

Also Published As

Publication number Publication date
EP2178851A1 (en) 2010-04-28
EP2178851B1 (en) 2011-12-28
EA201070148A1 (ru) 2010-06-30
TW200906823A (en) 2009-02-16
CN101743232A (zh) 2010-06-16
KR101157334B1 (ko) 2012-06-15
TN2010000028A1 (en) 2011-09-26
EA016475B1 (ru) 2012-05-30
CL2008002051A1 (es) 2009-05-29
PT2178851E (pt) 2012-02-27
ECSP109879A (es) 2010-02-26
MA31683B1 (fr) 2010-09-01
PE20090809A1 (es) 2009-06-27
HRP20120048T1 (hr) 2012-02-29
AR067540A1 (es) 2009-10-14
IL202234A0 (en) 2010-06-16
KR20100020999A (ko) 2010-02-23
CA2693406C (en) 2014-04-29
SI2178851T1 (sl) 2012-02-29
CO6270212A2 (es) 2011-04-20
DK2178851T3 (da) 2012-02-06
US20100152166A1 (en) 2010-06-17
ES2376176T3 (es) 2012-03-09
JP5373788B2 (ja) 2013-12-18
SV2010003458A (es) 2011-01-10
BRPI0814571A2 (pt) 2015-01-06
CA2693406A1 (en) 2009-01-22
JP2010533722A (ja) 2010-10-28
CY1112298T1 (el) 2015-12-09
US8153624B2 (en) 2012-04-10
ATE539065T1 (de) 2012-01-15
PL2178851T3 (pl) 2012-05-31
MX2010000502A (es) 2010-03-26
DOP2010000018A (es) 2010-01-31
AU2008276236B2 (en) 2013-03-14
AU2008276236A1 (en) 2009-01-22
CN101743232B (zh) 2013-03-06
WO2009012125A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
RS52216B (sr) Jedinjenja i metode za modulaciju fxr-a
AU2007291514B2 (en) Heterocyclic FXR binding compounds
US8106077B2 (en) Compounds and methods for modulating FXR
ES2255294T3 (es) Derivados de isoxazol sustituidos como moduladores del receptor de estrogenos.
US8193192B2 (en) Heterocyclic FXR binding compounds
WO2009149795A2 (en) Heterocyclic cyclopropyl-substituted fxr binding compounds
EA015632B1 (ru) Агонисты fxr
PT1828172E (pt) Derivados de pirrol com a actividade antagonista de receptor crth2
CN101287722A (zh) 作为代谢型谷氨酸受体拮抗剂的取代的哌嗪
TWI628166B (zh) 作為磷酸二酯酶抑制劑之１－苯基－２－吡啶基烷基醇衍生物
TW200800150A (en) Compounds with medicinal effects due to interaction with the glucocorticoid receptor
ES2342222T3 (es) Agonistas de fxr.
HU211690A9 (hu) Az átmeneti oltalom az 1—18. igénypontokra vonatkozik.
HK1146664B (en) P38 inhibitors and methods of use thereof